HFA Premium Access

Vepoloxamer (purified poloxamer-188) improves LV function, limits cardiomyocyte calcium overload and restores integrity of calciu cycling proteins in myocardium of dogs with advanced heart failure

Presentation

About the speaker

Professor Hani Sabbah

Henry Ford Hospital, Detroit (United States of America)
2 presentations
0 follower

5 more presentations in this session

Novel drugs in heart failure: what's on the horizon?

Speaker: Professor C. Maack (Wuerzburg, DE)

Thumbnail

Effects of serelaxin on a systolic cardiac dysfunction induced by isoproterenol in mice with increased cardiac aldosterone

Speaker: Doctor G. Billebeau (Paris, FR)

Thumbnail

Why treatment with natriuretic peptide analogs failed to fulfill our expectations? - receptor expression and function in a failing heart.

Speaker: Doctor K. Kodziszewska (London, GB)

Thumbnail

ORM-3819 promotes cardiac contractility on a dual mechanism of action: troponin-C dependent calcium sensitization is supported by selective PDE III inhibition

Speaker: Doctor L. Nagy (Debrecen, HU)

Thumbnail

Targeting HDACs in heart failure.

Thumbnail

Access the full session

Novel drugs - how do they work?

Speakers: Professor H. Sabbah, Professor C. Maack, Doctor G. Billebeau, Doctor K. Kodziszewska, Doctor L. Nagy
Thumbnail

About the event

Image

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk